Healthtech Startups
17,200 companies tagged Healthtech, with their investors and founders.
0 investors
0 investors
StrΕma Medical Corporation is a clinical-stage medical device company that has developed a patented laser system to permanently change eye color from brown, hazel, or black to lighter natural shades by removing surface iris pigment in an in-office procedure. The system is intended to be leased to refractive ophthalmologists worldwide.
0 investors
0 investors
0 investors
Structural Elements operates a franchise network of orthopedic wellness clinics using its proprietary (se) Treatment, a manual therapy and acupuncture method based on fascia mapping, postural alignment, and tensegrity-based assessment. It provides cash-based, root-cause care to patients across a national network of clinics in the US.
0 investors
0 investors
0 investors
Submersive is developing a spa and bathhouse concept that combines immersive art installations with bathing rituals and neuroscience-informed design, aiming to create therapeutic sensory experiences. It also functions as an R&D effort, testing environments on volunteers using wearables to gather biofeedback, with a first location planned in Austin, Texas.
0 investors
Sulfagenix develops SG1002, an oral hydrogen sulfide prodrug designed to treat oxidative stress-related diseases including cardiovascular disorders, cancer, and other chronic conditions. The company targets patients with conditions ranging from heart failure to cancer, diabetes, and neurodegeneration.
0 investors
SummaCor develops medical device technologies, including the LCAPP, for cardiac care led by a team of cardiologists and engineers. The company focuses on heart-related medical technology with clinical and advisory input from cardiology and heart failure specialists.
0 investors
0 investors
0 investors
0 investors
Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer. It licenses ivonescimab from Akeso for territories including the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Surface Ophthalmics is a biopharmaceutical company developing topical eyedrop treatments for dry eye syndrome and post-surgical ocular conditions. The company has evaluated multiple formulations through Phase II clinical trials and is pursuing three proprietary candidates for commercialization.
0 investors
0 investors
0 investors
0 investors